The Organ Nobody Was Treating

The diagnosis with no prescription

Around a third of adults worldwide have fat accumulating in their liver. Most of them do not know it. It has no symptoms worth noticing until it has already done structural damage, and by then the conversation is about fibrosis, cirrhosis and transplant lists.

It is now the leading cause of chronic liver disease, and it has been through several names. Fatty liver disease. NAFLD. Currently MASLD, metabolic dysfunction-associated steatotic liver disease.

Here is what made it strange. For decades this was a condition that doctors could diagnose precisely, stage accurately, and treat with nothing.

The prescription was a sentence: lose weight.

Think about what that sentence was actually asking, given everything in Part 1. It asked patients to defeat a metabolic control system with willpower, in order to treat an organ that was silently scarring, with no drug, no target, and no way to tell whether it was working short of another scan.

That was the standard of care. Not because anyone was negligent, but because there was nothing else to give.

The reversal you were asked to hold

In Part 2 I asked you to hold one result.

LY2409021 was a glucagon receptor antagonist, tested in people with type 2 diabetes. Blocking the glucagon receptor was a reasonable idea on paper, since glucagon raises blood glucose.

It increased liver fat.

That finding, published in 2017, was a warning sign for one approach. It was also a signpost, if you read it in the other direction. If switching that receptor off sends fat into the liver, what does switching it on do?

Most glucagon receptors in the body sit on hepatocytes. Liver cells. Glucagon drives lipolysis, inhibits lipogenesis and increases ketogenesis. The receptor that controls whether your liver stores fat or burns it was sitting there the entire time, with the arrow pointing the wrong way in every previous attempt.

Retatrutide points it the other way.

What happened when they looked

Sanyal and colleagues ran a phase 2a trial specifically on this question. Ninety-eight participants, all with MASLD and at least 10 percent liver fat, randomised to retatrutide at 1, 4, 8 or 12 mg or placebo, injected weekly, followed for 48 weeks. The primary readout was mean relative change in liver fat at 24 weeks.

At 24 weeks:

All of the retatrutide groups beat placebo at P less than 0.001.

Start at the bottom row. The placebo group's liver fat went up. Slightly, but up. That is the natural history of this condition when nothing effective is done, and it is the honest baseline against which everything else should be read.

Now the top dose. Eighty-two percent of the fat, gone from the liver, in 24 weeks.

The number that actually matters

Percentage reduction is a satisfying statistic and a slightly misleading one, because it depends where you started. A liver going from 30 percent fat to 5 percent and a liver going from 12 percent to 2 percent both look like large reductions, and only one of them was in serious trouble.

So the researchers reported the clinically meaningful threshold instead. Below 5 percent liver fat is considered normal. Not improved. Normal.

Proportion reaching normal liver fat at 24 weeks:

Eighty-six percent versus zero.

Not zero as a figure of speech. Zero participants on placebo, in a population who all began with at least 10 percent liver fat, reached a normal liver in 24 weeks.

The review summarises it as reversal of early-stage fatty liver disease in over 85 percent of participants, and calls for further work on whether this functions as a curative option for the condition. That is unusually direct language for a narrative review, and on these numbers it is not unreasonable.

The mechanism is not mysterious

The liver fat reduction tracked closely with changes in body weight, abdominal fat, and markers of insulin sensitivity and lipid metabolism. Nothing exotic is being claimed.

But the dose response is steep in a way that is worth noticing. Going from 1 mg to 12 mg roughly doubles the liver fat reduction and more than triples the proportion reaching a normal liver. That gradient is what you expect when a drug is acting directly on the organ, rather than the liver simply benefiting downstream from a smaller waistline.

Which lines up with where those receptors are.

Why this is the sleeper result

The weight loss figures get the headlines because weight is visible and everybody has an opinion about it.

The liver data may matter more, and for a boring reason: MASLD has no approved alternative, no symptoms, and an ugly endpoint. A patient with obesity has options, all of them difficult. A patient with a fatty liver and no access to these drugs has advice.

There is also a structural point here that sits underneath the whole series. Obesity was treated for decades as a cosmetic problem with medical consequences. What the liver data demonstrates is the reverse. It is a metabolic disease that happens to be visible, and the visible part was never the dangerous part.

The organ nobody was treating was the one quietly keeping score.

Where this stops

Ninety-eight people. Twenty-four weeks for the primary endpoint. Phase 2a, which is early.

Liver fat is also a surrogate. It is strongly associated with progression to fibrosis and cirrhosis, and reducing it is clearly desirable, but a trial measuring fat content is not a trial measuring who avoided cirrhosis fifteen years later. Nobody has run that trial, because nobody could have.

The review is explicit that further research into retatrutide as a treatment for fatty liver disease is necessary, and it is right.

In Part 5, I go through everything this paper admits about itself, everything the trials found that did not make the marketing, and what the phase 3 results confirmed and contradicted. It is the least exciting instalment and the most useful one.

This series covers a peer-reviewed narrative review of published trial data. Retatrutide has not been approved by the FDA. Nothing here is medical advice.